




Cancer Research

AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH




**Twenty-fifth Anniversary of the National Cancer Act:
Progress and Promise**

April 1, 1996
Volume 56 • Number 7
PP. 1471-1706
ISSN 0008-5472 • CNREA 8

A New Breed of
Molecular Biology Products

Telomerase Detection



The wait is over!


Oncor introduces the **TRAP-eze™ Telomerase Detection Kit**, the world's first commercially-available product for the detection of telomerase activity *in vitro*. Telomerase expression generally appears to be stringently repressed in normal human somatic cells, but reactivated in most cancer and immortalized cells. Using TRAP-eze™, telomerase expression can now be rapidly and accurately assayed in cells or tissue specimens.

TRAP-eze™ is an advanced version of the Telomeric Repeat Amplification Protocol (TRAP). In the TRAP assay, active telomerase (present in cell or tissue extracts) adds telomeric repeat DNA onto a substrate oligonucleotide, and the extended product is amplified by the polymerase chain reaction*. The reaction products are then **rapidly analyzed** on a

polyacrylamide gel: samples containing telomerase activity show the signature DNA laddering pattern shown above, whereas negatives do not.

TRAP-eze™ kit advancements include improved primer design which simplifies the technique and improves reliability, and a convenient, built-in internal PCR control that facilitates quantitative interpretation of the data. Most importantly, TRAP-eze™ is the **most sensitive** method of telomerase detection available, maximizing reaction yield from precious, small samples and permitting the detection of telomerase in mixed cell populations.

The wait is over – contact Oncor today for more information on this exciting breakthrough product!



oncor®

209 Perry Parkway
Gaithersburg,
MD 208 277

1-800-77-ONCOR
301-963-3500
Fax: 301-926-6129

<http://www.oncorinc.com/home>
techsvc@oncor.com
custsvc@oncor.com

Licensed from Geron Corporation. Patents pending.
For Research Use Only. Not for use in diagnostic procedures.

* The Polymerase Chain Reaction (PCR) process is covered by U.S. patents owned by Hoffmann-La Roche.

Use of the PCR process requires a license.
TRAP-eze™ is a trademark of Oncor, Inc.

ORIGINS OF BREAST AND PROSTATE CANCER

Special Conference Sponsored by
The General Motors Cancer Research Foundation
June 19 & 20, 1996

National Institutes of Health
Bethesda, Maryland

June 19, 1996: Breast Cancer

Introductory Remarks—Joseph G. Fortner, M.D.; Conference Perspective—Philip A. Sharp, Ph.D.; Geographic Variations and Time Trend Analysis of Breast Cancer—Robert N. Hoover, M.D.; Modeling of Breast Cancer Incidence: What Can Be Explained by Known Risk Factors—Graham A. Colditz, M.D., Dr.P.H.; Weight, Height, Diet and Breast Cancer—Walter Willett, M.D., Dr.P.H.; Environmental Chemicals as Causal Factors for Breast Cancer—Mary S. Wolff, Ph.D.; Role of Hormones in Breast Cancer Etiology—Penti Süteri, Ph.D., M.D.; Estrogen Receptor Structure and Function in Breast Cancer Cells—Geoffrey L. Green, Ph.D.; Mechanisms of Gene Activation and Repression by Steroid Receptors—Bert W. O'Malley, M.D.; Genetic Epidemiology of BRCA1 with Particular Reference to Premenopausal Breast Cancer in the Ashkenazic Jewish Population—Daniel Haber, M.D., Ph.D.; Mechanisms of Action of BRCA1 Protein—Wen-Hwa Lee, Ph.D.; Genomic Organization and Mutation Spectra of BRCA1 and BRCA2—Sean V. Tavtigian, Ph.D.; The EGFR Superfamily and Breast Cancer Progression—Marc Lippman, M.D.; Conference Overview—Brian Henderson, M.D.

June 20, 1996: Prostate Cancer

Geographic Variations in Prostate Cancer and the Effect of Migration—Laurence N. Kolonel, M.D., Ph.D.; Endogenous Hormones in Adulthood and Prostate Cancer Risk—Meir Stampfer, M.D.; Diet and Other Extrinsic Factors Influencing Prostate Cancer Risk—Edward Giovannucci, M.D., Sc.D.; Genetics of Prostate Cancer—Francis Collins, M.D.; Apoptosis and Tumor Invasion in Prostate Cancer—Martin Tenniswood, Ph.D.; Mechanism of Metastases of Prostate Cancer—Timothy Thompson, Ph.D.; Prostate Cancer: Summary and Interpretation of Conference—Philip W. Kantoff, M.D.

1:30 P.M.—Lectures by the 1996 Prizewinners of the General Motors Cancer Research Foundation Awards

Please preregister by contacting: Campbell, Peachey & Associates, 111 Quincy Place, N.E., Washington, D.C. 20002. Phone: 202/636-8745; Fax: 202/636-8755. Additional information is available; no registration fee.

This space contributed
as a public service.

**55 MILLION
PEOPLE TOOK OUR
FREE COURSE.**

Our public education programs teach people about cancer. Last year, 55 million people learned that with early detection we can win 87% of the battle. For more information on winning, call 1-800-ACS-2345.



**THERE'S NOTHING MIGHTIER
THAN THE SWORD.**

SENIOR/PRINCIPAL RESEARCH SCIENTIST

Be at the forefront of drug discovery research with The DuPont Merck Pharmaceutical Company. We are focused on meeting unmet medical needs through the discovery and development of innovative compounds leading to novel pharmaceuticals.

We have a position in our Cancer/Genetics Group for a cancer cell biologist to lead a laboratory focused on the development and implementation of cell-based screens and animal models for the identification and evaluation of selective anti-cancer agents. The applicant should possess good molecular biology and cell biology skills and preferably have prior experience in cancer biology/pharmacology. Previous work in the areas of cell cycle control or apoptosis and a background including clinical experience would be an asset. The applicant will work as part of a multi-disciplinary team aimed at the discovery of novel anti-cancer agents. Good writing and communication skills and the ability to collaborate effectively are essential. The candidate should have at least three years post-doctoral experience and a Ph.D., M.D., or M.D./Ph.D. in a cancer-related area.

Our location, near Wilmington, DE, offers an attractive lifestyle with easy access to all the cultural, academic and recreational activities of the Eastern Seaboard. The DuPont Merck Pharmaceutical Company can offer you an excellent compensation and benefits package including a 401K plan as well as excellent working conditions and challenging assignments. Please send a letter of introduction and resume to: Human Resources-SD/SPRS, The DuPont Merck Pharmaceutical Company, Experimental Station, 400/2413, P.O. Box 80400, Wilmington, DE 19880-0400. An equal opportunity employer M/F/D/V.



The DuPont Merck Pharmaceutical Company
Merging Strengths...Emerging Opportunities

CARCINOGENESIS FROM ENVIRONMENTAL POLLUTION: ASSESSMENT OF HUMAN RISK AND STRATEGIES FOR PREVENTION

Joint Meeting Organized by the
American Association for Cancer Research (AACR)
and the International Agency for Research on Cancer (IARC)

With the Collaboration of the Hungarian Cancer Society



October 6-9, 1996
Hotel Gellért
Budapest, Hungary



CONFERENCE CHAIRPERSONS

Frederica Perera / New York, USA
Paul Kleihues / Lyon, France

PROGRAM COMMITTEE

Hans-Olov Adami / Uppsala, Sweden
J. Carl Barrett / Research Triangle Park, USA
Paolo Boffetta / Lyon, France
Edward Bresnick / Worcester, USA
Mieczysław R. Chorąży / Gliwice, Poland
Joseph F. Fraumeni, Jr. / Bethesda, USA

Waun Ki Hong / Houston, USA
Margaret L. Kripke / Houston, USA
Kenneth Olden / Research Triangle Park, USA
Alán Pintér / Budapest, Hungary
Manfred F. Rajewsky / Essen, Germany
David Zaridze / Moscow, Russia

SCIENTIFIC PROGRAM

Keynote Address

Curtis C. Harris / Bethesda, USA

Cancer Incidence and Etiology

Witold A. Zatoński / Warsaw, Poland
Frederica Perera / New York, USA
J. Carl Barrett / Research Triangle Park, USA
Helmut Bartsch / Heidelberg, Germany

Air, Water, Food, and Soil Contamination

Radim J. Šrám / Prague, Czech Republic
Joellen Lewtas / Research Triangle Park, USA
Wiesław Jedrychowski / Cracow, Poland
Olav Axelson / Linköping, Sweden

Ambient, Environmental, and Occupation Exposure and Cancer Risk

Mieczysław R. Chorąży / Gliwice, Poland
Alán Pintér / Budapest, Hungary
Kimmo Peltonen / Helsinki, Finland
Monica C. Hollstein / Heidelberg, Germany
Karl Hemminki / Stockholm, Sweden

Tobacco

Ivan Plesko / Bratislava, Slovakia
Barbara S. Hulka / Chapel Hill, USA
Paolo L. Vineis / Turin, Italy
Stephen S. Hecht / Valhalla, USA
Krystyna Frenkel / New York, USA
Bernadette Schoket / Budapest, Hungary

Strategies for Prevention

Waun Ki Hong / Houston, USA
I. Bernard Weinstein / New York, USA
Anna Tompa / Budapest, Hungary

Roundtable Discussion

Paul Kleihues / Lyon, France
Hans-Olov Adami / Uppsala, Sweden
Paolo Boffetta / Lyon, France
Edward Bresnick / Worcester, USA
Andrew E. Czeizel / Budapest, Hungary
Terri Damstra / Research Triangle Park, USA
Edith Olah / Budapest, Hungary
Kenneth Olden / Research Triangle Park, USA
Manfred F. Rajewsky / Essen, Germany
William A. Suk / Research Triangle Park, USA
David Zaridze / Moscow, Russia

Applicants are encouraged to submit abstracts for poster presentation.

Information and Application Forms

American Association for Cancer Research
Public Ledger Building, Suite 816
150 S. Independence Mall West
Philadelphia, PA 19106-3483
(215) 440-9300 (215) 440-9313 (FAX)
Email: aacr@aol.com

THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER

The University of Texas M.D. Anderson Cancer Center Department of Urology

Multidisciplinary Prostate Cancer Research Program

The University of Texas M. D. Anderson Cancer Center is launching a major new integrated multidisciplinary program in Prostate Cancer Research in conjunction with the Departments of Urology, Cell Biology, and Genitourinary Medical Oncology. Ample resources of dedicated laboratory space and research personnel and a substantial financial base are being secured for this program. We are seeking scientists for faculty positions to add to our critical contingent of researchers interested in the biology and therapy of human prostate cancer.

- A position at the **Professor** level for a senior scientist with a record of outstanding achievement in research, extramural funding, administration, and graduate training;
- **Two** positions at the **Assistant** or **Associate Professor** level for scientists with exceptional accomplishments in cancer biology (systemic, cellular, molecular, and biochemical).

Candidates should have a Ph.D. or an M.D. degree with a track record of research in molecular biology and interest in the study of prostate cancer. Applicants should send *curriculum vitae*, a 1-2 page summary of research activities, and the names of three references to:

Andrew C. von Eschenbach, M.D.
Director of the Prostate Cancer Research Program
Chairman, Department of Urology, Box 110
The University of Texas M. D. Anderson Cancer Center
1515 Holcombe Blvd.
Houston, TX 77030

The University of Texas is an Affirmative Action/Equal Opportunity Employer and encourages minorities and women to apply. Smoke-free environment.

MAYO CLINIC DIVISION OF MEDICAL ONCOLOGY AND MAYO CANCER CENTER

Clinical Research Positions

The Division of Medical Oncology and the NCI-designated Mayo Cancer Center in Rochester, Minnesota, invite applications for two clinical research positions. Clinical investigators with established cancer research programs are encouraged to apply. The Mayo Clinic provides an outstanding environment for investigators interested in conducting translational research with the goal of improving prevention, diagnosis, and treatment of cancer. Interested applicants should submit a statement of research interests, curriculum vitae, bibliography, and list of references to:

James N. Ingle, M.D.
Associate Director for Clinical Research
Mayo Cancer Center
Mayo Clinic
200 First Street, SW
Rochester, MN 55905



Mayo Foundation is an affirmative action and equal opportunity educator and employer.

Texas Tech University Health Sciences Center

A Post-Doctoral Position is available immediately to study drug resistance and cancer. Candidate should have a Ph.D. or M.D. degree with background in drug resistance and molecular biology. Good salary, excellent working environment. Send curriculum vitae to:

Maria Claudia Mallarino, M.D.
Texas Tech University Health Sciences Center
Oncology Division
Department of Internal Medicine
3601 4th Street
Lubbock, Texas 79430

Phone: (806) 743-3155; Fax: (806) 743-3148

COVER LEGEND



With the stroke of a pen 25 years ago—December 23, 1971—President Richard Nixon signed into law legislation that would give new hope to millions of American men, women, and children. The “National Cancer Act of 1971” recommitted the nation to making the eradication of cancer a national priority.

This landmark legislation fostered extraordinary basic science, training opportunities, and rapid translation of research progress into clinical practice. It unraveled the fundamental knowledge necessary to advance cancer prevention and gave birth to the biotechnology industry. It authorized the first cancer centers, established cancer control programs, and created programs to disseminate scientific information about cancer. It led to basic science advances that have provided insights into many chronic diseases of humankind in addition to cancer. Cornerstones of the National Cancer Program such as the National Cancer Advisory Board (NCAB), the President’s Cancer Panel, and the special authorities of the Director of the National Cancer Institute (NCI) were first conceptualized under the National Cancer Act of 1971.

Many individuals were responsible for the passage of the National Cancer Act. Pictured on the cover are Senator Edward M. Kennedy (D-MA) (*top right*), Senator Ralph Yarborough (D-TX) (*bottom center*), Congressman Paul Rogers (D-FL)

(*top left*), Chairman of the Yarborough Commission Benno C. Schmidt (*bottom right*), and philanthropist and medical research advocate Mary Woodard Lasker (*bottom left*). We are indebted to these individuals and to all who have contributed to the success of the National Cancer Program.

Since 1971, the annual federal appropriation for the NCI has increased from \$200 million to more than \$2.25 billion in 1996. With this level of funding, we have achieved unparalleled research success and made tremendous investments in the nation’s health and in hope for the millions of Americans who will be diagnosed with cancer in their lifetime. Approximately 40% of Americans will develop cancer and one out of 4 Americans will die from cancer. By the turn of the century, cancer will be the leading cause of death in the United States and will be responsible for over 6 million years of productive life prematurely lost each year.

Our research opportunities have never been greater; our national debt has never been more daunting. Over the next five to seven years, our nation’s leaders will be reconsidering our national priorities and reconfiguring economic investments made with taxpayers’ dollars. The cancer research community must be strong and unanimous in working to ensure that economic impediments and concerns do not cripple our research progress and hinder our national capacity to explore new research frontiers. Our mandate for the next decade is to sustain the investment in cancer research opportunities which offer great promise. This investment will accelerate our progress against cancer by developing capabilities which will address all cancers.

The legacy of the National Cancer Act and its success to date pose a challenge for every member of the cancer research community. Each of us must be involved in working with the public and with policymakers to communicate our research progress and the success of our discovery process, to identify what support is necessary to maintain a vital research program, and to push the frontiers of research to eradicate all cancers.

As we accept this challenge, let us renew our vision for cancer research. In the words of Mary Woodard Lasker, “. . .the fruits of our labors throughout the years will: alleviate pain where there is suffering; provide the freedom to live in health so that we can fulfill our promise and quest in the pursuit of happiness; and provide hope where none existed before.”

Joseph R. Bertino
President, AACR